Uğur Şahin, BioNTech CEO (Bernd von Jutrczenka/dpa via AP Images)

Ex­clu­sive: BioN­Tech ac­quires lipid nanopar­ti­cle start­up found­ed by George Ma­son and UPenn sci­en­tists

BioN­Tech, the Ger­man drug com­pa­ny fa­mous for de­vel­op­ing a Covid-19 vac­cine with Pfiz­er, has ac­quired Aex­eR­NA and its nov­el lipid nanopar­ti­cles for mR­NA med­i­cines, End­points News has learned.

Aex­eR­NA is a tiny start­up that large­ly ex­ists on pa­per. It has no lab or staff sci­en­tists, just a for­mer patent lawyer as its CEO and sev­er­al sci­en­tif­ic co-founders, in­clud­ing mR­NA pi­o­neer and re­cent No­bel Prize lau­re­ate Drew Weiss­man from the Uni­ver­si­ty of Penn­syl­va­nia, and bio­engi­neer Michael Buschmann of George Ma­son Uni­ver­si­ty.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.